Bio-Techne Corporation TECH
72.72 USD -0.01 (-0.01%)
Nov 5, 2026, 11:44 AM EST
72.70 Day range 72.80
43.30 52-week range 72.73
- YTD
- +23.66%
- 1 year
- +21.32%
News
prnewswire.com BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September…
zacks.com Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock? TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.
seekingalpha.com Conestoga SMid Cap Composite Q3 2026 Portfolio Activity We initiated a position in Allegro because vehicle electrification, driver-assistance systems and other electronic features are increasing chip content per vehicle. We initiated a position in…
globenewswire.com Press release: CMB.TECH fleet update Antwerp, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one Suezmax, generating a…
globenewswire.com CMB.TECH SPECIAL GENERAL MEETING RESULTS Antwerp, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ANTWERP, Belgium, 8 October 2026, 15:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs:…
benzinga.com Bio-Techne Opens New Bristol Facility Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent…
prnewswire.com Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent…
zacks.com INCY or TECH: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
prnewswire.com INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE (CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration…
defenseworld.net Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy? Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) hit a new 52-week high on Monday. The company traded as high as $72.70 and last traded at $72.70, with a volume of 2660 shares trading…
newsfilecorp.com Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the "Company") has entered into a definitive Merger and Acquisition Agreement dated September 28, 2026,…
benzinga.com Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the…
prnewswire.com Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne…
prnewswire.com Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA…
zacks.com Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? Techne (TECH) reported earnings 30 days ago. What's next for the stock?
gurufocus.com $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN PR Newsw
seekingalpha.com CMB.TECH: Updates From Our Top Shipping Pick Of 2026 CMB.TECH delivered a 134% return in under a year, driven by a strategic dry bulk focus and strong tanker markets. I recently interviewed the CEO and CFO to get updates on the dry bulk industry and…
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH) BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
globenewswire.com PRESS RELEASE: CMB.TECH announces special general meeting on 8 October 2026 ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) invites…
benzinga.com Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026 Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore…
prnewswire.com Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More…
seekingalpha.com CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade) CMB.TECH (CMBT) shows improved earnings quality as core shipping EBITDA rises despite reduced ship sales. Q2 revenue and EBITDA surged, but backlog growth stalled, raising concerns about long-term…
seekingalpha.com CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript- benzinga.com Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73 Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
- benzinga.com Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period…
benzinga.com Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.- benzinga.com RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73 RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.
benzinga.com TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73 TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.
benzinga.com Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73 Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.- benzinga.com Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73 Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
benzinga.com Baird Maintains Neutral on Bio-Techne, Raises Price Target to $73 Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Neutral and raises the price target from $49 to $73.- benzinga.com Bio-Techne To Pay Termination Fee Of $230.5M To Merck KGaA In Event That Deal Isn't Consummated; Merck KGaA To Pay Fee Of $576.1M If Deal Terminated Termination Fees The Company will be required to pay to Parent a termination fee equal to $230,455,000 (the "Company Termination Fee"): · If (A) the Merger Agreement is validly terminated (i) by…
benzinga.com Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today Micron's blowout earnings powered memory and chip stocks higher, but the broad stock market rally stalled by midday as S&P 500 slipped.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
benzinga.com Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…- benzinga.com CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ:TECH), a Minneapolis-based global provider of life science tools, analytical technologies,…
- benzinga.com 'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News https://www.bloomberg.com/news/articles/2026-06-15/activist-investor-ananym-urges-bio-techne-to-consider-selling
benzinga.com Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65 Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and announces Price Target of $65.
benzinga.com Bio‑Techne And Refeyn Launch An Integrated Workflow To Characterize Charge And Size Variants In Bispecific Antibodies And Biosimilars By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge…
benzinga.com RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.- benzinga.com Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $70 Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.
- benzinga.com Wells Fargo Maintains Overweight on Bio-Techne, Lowers Price Target to $62 Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $76 to $62.
- benzinga.com Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $50 Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $54 to $50.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.
benzinga.com Bio-Techne Q3 2026 Earnings Call: Complete Transcript - benzinga.com Bio-Techne Q3 Adj. EPS $0.53 Misses $0.54 Estimate, Sales $311.415M Miss $317.093M Estimate Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.54 by 1.85 percent. This is a 5.36 percent decrease over earnings of $0.56…
- benzinga.com Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54 Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $68 to $54.